Orthopaedic Surgery, University of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA; Orthopaedic Surgery, Columbia University Medical Center, The Spine Hospital, New York-Presbyterian Healthcare System, New York, NY 10034, USA.
Orthopaedic Surgery, University of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA.
Spine J. 2018 Nov;18(11):1974-1981. doi: 10.1016/j.spinee.2018.03.018. Epub 2018 Apr 10.
Limited or no data exist evaluating risk factors associated with prolonged opioid use following cervical arthrodesis.
The objectives of this study were to assess trends in postoperative narcotic use among preoperative opioid users (OUs) versus non-opioid users (NOUs) and to identify factors associated with postoperative narcotic use at 1 year following cervical arthrodesis.
STUDY DESIGN/SETTING: This is a retrospective observational study.
The patient sample included 17,391 patients (OU: 52.4%) registered in the Humana Inc claims dataset who underwent anterior cervical fusion (ACF) or posterior cervical fusion (PCF) between 2007 and 2015.
Prolonged opioid usage was defined as narcotic prescription filling at 1 year following cervical arthrodesis.
Based on preoperative opioid use, patients were identified as an OU (history of narcotic prescription filled within 3 months before surgery) or a NOU (no preoperative prescription). Rates of opioid use were evaluated preoperatively for OU and trended for 1 year postoperatively for both OU and NOU. Multivariable regression techniques investigated factors associated with the use of narcotics at 1 year following ACF and PCF. Based on the model findings, a web-based interactive app was developed to estimate 1-year postoperative risk of using narcotics following cervical arthrodesis (http://neuro-risk.com/opiod-use/ or https://www.neurosurgerycost.com/opioid/opioid_use).
Overall, 87.4% of the patients (n=15,204) underwent ACF, whereas 12.6% (n=2187) underwent PCF. At 1 month following surgery, 47.7% of NOUs and 82% of OUs had a filled opioid prescription. Rates of prescription opioids declined significantly to 7.8% in NOUs versus 50.5% in OUs at 3 months, but plateaued at the 6- to 12-month postoperative period (NOU: 5.7%-6.7%, OU: 44.9%-46.9%). At 1 year, significantly higher narcotic prescription filling rates were observed in OUs compared with NOUs (45.3% vs. 6.3%, p<.001). Preoperative opioid use was a significant driver of 1-year narcotic use following ACF (odds ratio [OR]: 7.02, p<.001) and PCF (OR: 6.98, p<.001), along with younger age (≤50 years), history of drug dependence, and lower back pain.
Over 50% of the patients used opioids before cervical arthrodesis. Postoperative opioid use fell dramatically during the first 3 months in NOU, but nearly half of the preoperative OUs will remain on narcotics at 1 year postoperatively. Our findings serve as a baseline in identifying patients at risk of chronic use and encourage discontinuation of opioids before cervical spine surgery.
目前关于颈椎融合术后长期使用阿片类药物的相关风险因素,仅有少量或缺乏数据。
本研究旨在评估颈椎融合术前使用阿片类药物的患者(OUs)与非使用阿片类药物的患者(NOUs)术后麻醉药物使用的趋势,并确定术后 1 年使用麻醉药物的相关因素。
研究设计/设置:这是一项回顾性观察性研究。
患者样本包括在 2007 年至 2015 年间接受前路颈椎融合术(ACF)或后路颈椎融合术(PCF)的 Humana Inc 索赔数据集中的 17391 名患者(OU:52.4%)。
长期使用阿片类药物定义为颈椎融合术后 1 年内的麻醉药物处方。
根据术前阿片类药物的使用情况,将患者确定为 OU(术前 3 个月内有麻醉药物处方)或 NOU(无术前处方)。评估 OU 术前的麻醉药物使用情况,并对 OU 和 NOU 术后 1 年的麻醉药物使用情况进行趋势分析。多变量回归技术调查了与 ACF 和 PCF 术后 1 年使用麻醉药物相关的因素。根据模型结果,开发了一个基于网络的交互式应用程序,用于估计颈椎融合术后 1 年使用麻醉药物的风险(http://neuro-risk.com/opiod-use/或 https://www.neurosurgerycost.com/opioid/opioid_use)。
总体而言,87.4%的患者(n=15204)接受了 ACF,12.6%(n=2187)接受了 PCF。术后 1 个月,47.7%的 NOUs 和 82%的 OUs 有麻醉药物处方。NOUs 的麻醉药物处方比例显著下降至术后 3 个月的 7.8%,而 OUs 则降至 50.5%,但在术后 6-12 个月时趋于稳定(NOUs:5.7%-6.7%,OUs:44.9%-46.9%)。术后 1 年,OU 的麻醉药物处方比例明显高于 NOUs(45.3%比 6.3%,p<.001)。术前使用阿片类药物是 ACF(比值比[OR]:7.02,p<.001)和 PCF(OR:6.98,p<.001)术后 1 年使用麻醉药物的显著驱动因素,同时还包括年龄较小(≤50 岁)、药物依赖史和下腰痛。
超过 50%的患者在颈椎融合术前使用阿片类药物。NOUs 患者在术后前 3 个月内的麻醉药物使用量急剧下降,但近一半的术前 OUs 在术后 1 年内仍将继续使用麻醉药物。我们的研究结果为识别有慢性使用风险的患者提供了一个基线,并鼓励在颈椎手术前停止使用阿片类药物。